Foundation Medicine said this week that is has inked a strategic collaboration with Sanofi for cancer biomarkers.

Under the agreement, the Cambridge, Mass.-based company will use its genomic sequencing and analysis expertise to identify genetic biomarkers and potential companion diagnostics for certain oncology drug candidates from Sanofi.

The partnership with Sanofi adds to four other collaborations Foundation has established with pharmaceutical firms, including Johnson & Johnson Pharmaceutical Research and Development, Novartis, and Celgene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.